Product

HM95573

Aliases

HM95573, cobimetinib

1 clinical trial

2 indications

Indication

Locally Advanced Solid Tumor

Indication

Metastatic Solid Tumor

Clinical trial

A Phase Ib, Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2024-09-30